https://www.thebodypro.com/category/descovy-pro

Emtricitabine/Tenofovir Alafenamide (Descovy)

The Latest

pill bottles and cash
Conference Coverage

A PrEP Pricing Pickle: Descovy Will Need a Drastic Discount to Be Worthwhile, Study Finds

With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.

By Myles Helfand
Peter Staley Brenda Emily Goodrow and Mark Lemley credit Ivy Arce
Interviews

Oral Arguments in Antitrust Case Against HIV Drug Companies Began Last Week. Plaintiff Peter Staley Explains the Case

The case could change the way pharma companies make agreements to keep generic versions of single-tablet pills at bay.

By Terri Wilder, M.S.W.
Senior woman receives prescription medication from doctor
News Analysis

Should All PrEP Users on Truvada Switch to Descovy? These Leading Docs Say, ‘Not So Fast.’

Many fear the push to put more people on the new brand-name drug before Truvada goes generic this year.

By Larry Buhl
Timothy Ray Brown at the Association of Nurses in AIDS Care (ANAC) in Portland, Oregon
News

The Berlin Patient, the First Person Ever Cured of HIV, on Taking PrEP: "I Want a Full Sexual Life"

Timothy Ray Brown, known as "the Berlin patient," has begun taking PrEP to make sure he doesn't have to deal with an HIV diagnosis -- again.

By Sony Salzman
Facebook logo reflected in an eye
News Analysis

Misleading Ads About PrEP Are Threatening Progress to End the HIV Epidemic. They Must Be Removed.

Pre-exposure prophylaxis (PrEP) is a vital part of ending HIV, but ads targeting people to join lawsuits are planting needless fears in patients, three leading HIV specialists write.

By Demetre C. Daskalakis, M.D., M.P.H., Oni Blackstock, M.D., M.H.S. and David Holland, M.D., M.H.S.
young man looking at pill before taking it
News

FDA Approves Descovy for PrEP, but Only for Cisgender Men and Transgender Women

The FDA approved the fixed-dose combination of emtricitabine and tenofovir alafenamide for PrEP, but advocates hope to see more research on the HIV prevention drug's efficacy for receptive vaginal sex for cisgender women and transgender men.

By Sony Salzman
Conference Centre at 10th IAS Conference on HIV Science (IAS 2019), Mexico City, Mexico
Conference Coverage

Does Descovy Really Work Better Than Truvada for PrEP? One Researcher Raises Questions About the DISCOVER Trial Results

Newly presented data from IAS 2019 spark discussion about study populations, study endpoints, and potential weight gain.

By Terri Wilder, M.S.W.
Christoph D. Spinner
Conference Coverage

DISCOVER PrEP Trial Finds F/TAF Has Superior Load Time and Tail Compared to F/TDF

But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.

By Sony Salzman
illustration of person on cliff with arms raised as sun rises/sets
News

This Week in HIV Research: From PrEP to Treatment, There's Always More to Learn

April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.

By Barbara Jungwirth and Myles Helfand
Promo Image
News

This Week in HIV Research: Renal Upsides for Tenofovir Alafenamide

E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.

By Barbara Jungwirth and Myles Helfand